ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2017
Health-related quality of life across all stages of autosomal dominant polycystic kidney disease.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Exercise training for adults undergoing maintenance dialysis.The Cochrane database of systematic reviews · 2022Pooled it
- Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.BMC nephrology · 2019Trial
- Health-related quality of life in people with autosomal dominant polycystic kidney disease: a systematic review.Clinical kidney journal · 2026Article
- Association of Kidney Volume With Patient-Reported Outcomes in ADPKD.Kidney international reports · 2026Article
- Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR Registry.Canadian journal of kidney health and disease · 2026Article
- End Point Selection in ADPKD Clinical Trials.Kidney international reports · 2025Review
- Digital physical activity intervention via the Kidney BEAM platform in patients with polycystic kidney disease: a randomized controlled trial.Clinical kidney journal · 2025Article
- Association between cognitive functioning and health-related quality of life and its mediation by depressive symptoms in older patients with kidney failure.Journal of nephrology · 2024Observational
- Review
- Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease.Clinical kidney journal · 2024Article
- Review
- Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.Kidney medicine · 2024Article
- The impact of pre-transplantation nephrectomy on quality of life in patients with autosomal dominant polycystic kidney disease.World journal of urology · 2023Article
- Polycystic Kidney Disease Drug Development: A Conference Report.Kidney medicine · 2023Article
- Caregiver Burden of Autosomal Dominant Polycystic Kidney Disease: A Qualitative Study.Kidney medicine · 2023Article
- Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study.Clinical kidney journal · 2022Article
- Article
- Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report.Clinical kidney journal · 2022Article
- Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study.International journal of nephrology and renovascular disease · 2021Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA limited number of studies have assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease (ADPKD). Results to date have been conflicting and studies have generally focused on patients with later stages of the disease. This study aimed to assess HRQoL in ADPKD across all stages of the disease, from patients with early chronic kidney disease (CKD) to patients with end-stage renal disease.
methodsA study involving cross-sectional patient-reported outcomes and retrospective clinical data was undertaken April-December 2014 in Denmark, Finland, Norway and Sweden. Patients were enrolled into four mutually exclusive stages of the disease: CKD stages 1-3; CKD stages 4-5; transplant recipients; and dialysis patients.
resultsOverall HRQoL was generally highest in patients with CKD stages 1-3, followed by transplant recipients, patients with CKD stages 4-5 and patients on dialysis. Progressive disease predominately had an impact on physical health, whereas mental health showed less variation between stages of the disease. A substantial loss in quality of life was observed as patients progressed to CKD stages 4-5.
conclusionsLater stages of ADPKD are associated with reduced physical health. The value of early treatment interventions that can delay progression of the disease should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.